Publisher
source

Instituto de Investigação e Inovação em Saúde da Universidade do Porto

Just Landed

PhD holder researcher in Oncobiology Instituto de Investigação e Inovação em Saúde da Universidade do Porto in Portugal

Degree Level

PhD

Field of study

Immunotherapy

Funding

Available

Deadline

Oct 8, 2026

Country flag

Country

Portugal

University

Instituto de Investigação e Inovação em Saúde da Universidade do Porto

Social connections

How do I apply for this?

Sign in for free to reveal details, requirements, and source links.

More information can be found here

Keywords

Immunotherapy
Cancer Biology
Biology
Cancer Research
Transcriptional Profiling
Tumor Immunology

Suggested positions

About this position

i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto is opening an international call for a PhD holder researcher in Oncobiology. The position is based in Porto, Portugal, within the research group Intercellular Communication and Cancer.

The project focuses on PSGL-1 immune checkpoint protein antibody blockade as a strategy to treat non-Hodgkin lymphoma. The work is highly translational and combines tumor immunology, lymphoma biology, and therapeutic evaluation in preclinical models. The research aims include studying how PSGL-1 blockade changes immune-cell phenotypes and transcriptional programs inside lymphomas, and testing whether anti-PSGL-1 therapy improves responses when combined with other treatments such as anti-CD20 therapy, immune checkpoint inhibitors, doxorubicin, or low-dose radiotherapy.

The successful candidate will work with the A20 mouse lymphoma syngeneic model, advanced characterization of the lymphoma microenvironment, T-cell-deficient mouse experiments, autologous co-cultures with patient lymphoma T cells, and multiparameter flow cytometry. This is a strong opportunity for researchers interested in cancer immunotherapy, hemato-oncology, and experimental oncology using mouse models and immune profiling.

The post is for a junior researcher under an unfixed-term work contract, with a monthly remuneration of €2,408.11, funded by national funds through FCT. The anticipated start date is 1 December 2026, subject to budget availability, and the expected duration is 12 months, eventually extendable.

Eligibility highlights include a PhD in Oncobiology or a related area, a peer-reviewed publication record, extensive hands-on expertise in hemato-oncology, proven experience with cancer mouse models, DGAV authorization for laboratory animal work, strong English skills, teamwork, and immediate availability. Preference may be given to candidates with broader DGAV animal-licence coverage and experience in managing research projects.

Applications must be submitted online in PDF format between 24 September 2026 and 8 October 2026. Required documents include proof of PhD, detailed CV, the laboratory-animal license, a motivation letter in English, and any other relevant evidence of qualifications.

Funding details

Available

What's required

Mandatory: PhD degree in Oncobiology or related areas; motivation letter in English; relevant publication record in peer-reviewed journals in oncobiology; extensive hands-on expertise in hemato-oncology; proven experience in cancer mouse model studies; DGAV license to work with laboratory animals for A+D functions; fluency in written and spoken English; good teamwork and interpersonal skills; immediate availability to start the contract. Preferential: DGAV license for A+B+D functions; experience in managing research projects is valued.

How to apply

Submit the required documents in PDF format through the online application link. Include proof of PhD degree, detailed CV, DGAV animal-licence documentation, motivation letter in English, and any other relevant supporting documents. Applications are accepted from 2026-09-24 until 2026-10-08.

Ask ApplyKite AI

Start chatting
Can you summarize this position?
What qualifications are required for this position?
How should I prepare my application?